Results 121 to 130 of about 117,694 (268)

Integrated Engineering of CAR‐T Cells for Solid Tumours

open access: yesCell Proliferation, EarlyView.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang   +5 more
wiley   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond   +6 more
wiley   +1 more source

Subgingival instrumentation

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract The S3‐level clinical guidelines for the treatment of patients with periodontitis stages I–III published by the European Federation of Periodontology in 2020, suggest a pre‐established stepwise approach for oral‐healthcare professionals with precise therapeutic pathways.
Cristiano Tomasi   +2 more
wiley   +1 more source

CD19 CAR T cells for B-ALL with EMD. [PDF]

open access: yesBlood Adv
Llaurador Caraballo G, Steffin D.
europepmc   +1 more source

Junctional Adhesion Molecule‐A (JAM‐A) Associates With High‐Risk Disease in Multiple Myeloma Patients and a Structure‐Based Rationally‐Designed Peptide Inhibitor Attenuates Tumorigenic Features In Vitro and In Vivo

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley   +10 more
wiley   +1 more source

CRLF2 rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: a possible link? [PDF]

open access: yesBlood Adv
Gava F   +16 more
europepmc   +1 more source

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

Discovery of a cryptic aminoacidic triad involved in the temperature adaptation of GH1 enzymes

open access: yesThe FEBS Journal, EarlyView.
Cold‐active enzymes retain high catalytic activity at low temperatures but are characterized by thermal instability, a behavior not fully understood. Comparison between a cold‐active GH1 and its mesophilic counterparts highlights the role of a three‐residue motif (W‐M‐F) in conferring structural stability to a mesophilic GH1.
Stefania Digiovanni   +5 more
wiley   +1 more source

MSLN expression predicts a high risk of EMD in AML by promoting cell adhesion and metastasis via interaction with MUC16. [PDF]

open access: yesBlood Adv
Wang L   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy